Skip to main content

Market Overview

Alexion Offer for Wilson Therapeutics Accepted

Share:

– Offer accepted by shareholders representing 97.7% of shares and
votes in Wilson Therapeutics –

Alexion
Pharmaceuticals, Inc.
(NASDAQ:ALXN) today announced that its offer,
through a wholly owned subsidiary, for the shares in Wilson Therapeutics
has been accepted by shareholders representing 97.7 percent of the total
number of shares and votes in Wilson Therapeutics. The acquisition has
also been approved by relevant regulatory authorities. As more than 90
percent of the total number of shares have been tendered and all
conditions of the offer have been fulfilled, the offer has been declared
unconditional and settlement of the tendered shares will occur on May
30, 2018.

"The acquisition of Wilson Therapeutics is a key first step in
rebuilding our pipeline," said Ludwig Hantson, Ph.D., Chief Executive
Officer of Alexion. "We look forward to using our significant experience
in rare metabolic and neurological diseases to improve treatment for
patients with Wilson disease through the development of WTX101, which
has the potential to be the first new treatment in more than 20 years
and become the new standard of care for Wilson disease."

In order to give Wilson Therapeutics' shareholders additional time to
accept the offer, Alexion has extended the acceptance period until June
8, 2018. Settlement for shares tendered during this extended acceptance
period is expected on June 15, 2018.

Alexion intends to initiate compulsory redemption proceedings regarding
the remaining shares in Wilson Therapeutics as well as to promote a
delisting of the shares from Nasdaq Stockholm.

For additional details on the transaction, please visit http://ir.alexion.com/acquisitions.cfm.

About Wilson Disease

Wilson disease is a rare, chronic, genetic, and potentially
life-threatening liver disorder of impaired copper transport. Copper
balance is normally maintained in the body by hepatic excretion of
excessive copper in the bile. In patients with Wilson disease, a genetic
mutation disables this biliary excretion pathway and excess copper
accumulates over time in the liver cells. The accumulation of copper
eventually overwhelms safe storage capacity and cellular injury occurs.
When the liver's capacity for copper storage is exceeded, and when liver
cells are injured, copper is released into the circulation and may
accumulate in other organs, including the central nervous system.
Untreated, Wilson disease leads to various combinations and severity of
hepatic, neurologic, and psychiatric symptoms, and can be fatal.1,2

Wilson disease affects approximately one in every 30,000 people
worldwide.3 The average age of diagnosis is 15-20 years,3
with the majority of patients presenting between the ages of 10 and 30.4
Current standard of care includes metal chelators to remove serum
copper, followed by maintenance with zinc to prevent re-accumulation.1,2
There have been no new treatment options approved in over two decades
and a significant unmet need still exists for patients.

About WTX101

WTX101 (bis-choline tetrathiomolybdate) is a first-in-class
copper-binding agent with a unique mechanism of action, under
investigation as a novel therapy for Wilson disease. In contrast to
current treatments, WTX101 provides an alternative copper-protein
binding mechanism by forming a tripartite complex with copper and
albumin. WTX101 thereby detoxifies excess copper in both liver and
blood, and promotes copper clearance through biliary excretion (the
body's natural route of elimination). WTX101 has a 10,000-fold higher
affinity for copper than other chelators and addresses the underlying
cause of the disease.

A Phase 2 study evaluating the efficacy and safety of WTX101 in patients
with Wilson disease has been completed successfully.5 In
addition, the active moiety of WTX101, tetrathiomolybdate, has been
tested in several previous clinical studies in Wilson disease patients.
The data from these studies suggest that WTX101 can reduce and control
free copper levels and improve symptoms and associated disabilities. The
data also suggest that WTX101 is generally well tolerated with a low
risk of drug-induced neurological worsening. WTX101 has received Fast
Track designation in the U.S. and Orphan Drug Designation for the
treatment of Wilson disease in the U.S. and EU.

About Alexion

Alexion is a global biopharmaceutical company focused on serving
patients and families affected by rare diseases through the innovation,
development, and commercialization of life-changing therapies. Alexion
is the global leader in complement inhibition and has developed and
commercializes the first and only approved complement inhibitor to treat
patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical
hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR)
antibody-positive generalized myasthenia gravis (gMG). In addition,
Alexion has two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As
the leader in complement biology for over 20 years, Alexion focuses its
research efforts on novel molecules and targets in the complement
cascade, and its development efforts on the core therapeutic areas of
hematology, nephrology, neurology, and metabolic disorders. This press
release and further information about Alexion can be found at: www.alexion.com.

[ALXN-G]

Forward-Looking Statement

This press release contains forward-looking statements, including
statements related to the potential benefits of WTX101 for the treatment
of Wilson disease and the potential benefits of the transaction.
Forward-looking statements are subject to factors that may cause
Alexion's results and plans to differ from those expected, including for
example, decisions of regulatory authorities regarding the adequacy of
our research, marketing approval or material limitations on the
marketing of our products, delays, interruptions or failures in the
manufacture and supply of our products and our product candidates,
failure to satisfactorily address matters raised by the U.S. Food and
Drug Administration and other regulatory agencies, the possibility that
results of clinical trials are not predictive of safety and efficacy
results of our products in broader patient populations, the possibility
that clinical trials of our product candidates could be delayed, the
risk that anticipated regulatory filings are delayed, the risk that
estimates regarding the number of patients with Wilson disease are
inaccurate, and a variety of other risks set forth from time to time in
Alexion's filings with the SEC, including but not limited to the risks
discussed in Alexion's Quarterly Report on Form 10-Q for the period
ended March 31, 2018 and in our other filings with the SEC. Alexion does
not intend to update any of these forward-looking statements to reflect
events or circumstances after the date hereof, except when a duty arises
under law.

References

1 Roberts, E. and M.L. Schilsky (2008). "Diagnosis and
Treatment of Wilson Disease: An Update." Hepatology 47(6):
2089-2111.

2 European Association for the Study of the Liver (2012).
"EASL clinical practice guidelines: Wilson's Disease". J Hepatol
6(53): 671-685.

3 Merle, U. et al., (2007). "Clinical presentation, diagnosis
and long-term outcome of Wilson's disease: a cohort study." Gut
56: 115-120.

4 Beinhardt, S. et al., (2014). "Long-term outcomes of
patients with Wilson disease in a large Austrian cohort." Clin
Gastroenterol Hepatol
12: 683-689.

5 Weiss, K.H. et al., (2017). Bis-choline tetrathiomolybdate
in patients with Wilson's disease: an open-label, multicentre, phase 2
study. Lancet Gastroenterol Hepatol 2(12): 869-876.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com